ACHV Stock Summary and Trading Ideas (Achieve Life Sciences - Common Shares | NASDAQ:ACHV)

Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Achieve Life Sciences - Common Shares trades on the NASDAQ stock market under the symbol ACHV.

As of October 30, 2026, ACHV stock price declined to $6.83 with 1,325,707 million shares trading.

ACHV has a beta of 3.91, meaning it tends to be more sensitive to market movements. ACHV has a correlation of 0.25 to the broad based SPY ETF.

ACHV has a market cap of $704.19 million. This is considered a Small Cap stock.

In the last 3 years, ACHV traded as high as $8.64 and as low as $1.84.

The top ETF exchange traded funds that ACHV belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

ACHV has outperformed the market in the last year with a price return of +30.3% while the SPY ETF gained +12.3%. ACHV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +8.4% and +7.1%, respectively, while the SPY returned +2.1% and -1.0%, respectively.

ACHV support price is $6.92 and resistance is $7.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACHV shares will trade within this expected range on the day.